Compugen enhances LINKS platform
November 2016

HOLON, Israel—In late August, Compugen Ltd. disclosed that its LINKS computational platform, initially designed for the characterization and differentiation of existing novel drug target candidates, has been enhanced to include the in-silico discovery of new immuno-oncology drug targets, with a specific focus on the discovery of myeloid targets within the tumor microenvironment (TME). LINKS now allows Compugen to broaden its existing repertoire of immune checkpoint targets. This further development of LINKS, a component of the company’s broader predictive discovery infrastructure, included the integration of additional public and proprietary data in order to allow the identification and analysis of specific immune cell types derived from the TME and, in particular, myeloid cells through the integration of multiple data types across a range of conditions, diseases, stimuli and specific myeloid sub- populations.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.